This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2012 Jun 1;11(6):435-6.

doi: 10.1038/nrd3744.

Outlook for the next 5 years in drug innovation

Roy Berggren, Martin Møller, Rachel Moss, Pawel Poda, Katarzyna Smietana

PMID: 22653208
DOI: 10.1038/nrd3744

Outlook for the next 5 years in drug innovation

Roy Berggren et al. Nat Rev Drug Discov. 2012.

. 2012 Jun 1;11(6):435-6.

doi: 10.1038/nrd3744.

Authors

Roy Berggren, Martin Møller, Rachel Moss, Pawel Poda, Katarzyna Smietana

PMID: 22653208
DOI: 10.1038/nrd3744

No abstract available

PubMed Disclaimer

Similar articles

Discontinued drugs in 2010: oncology drugs.
Williams R. Williams R. Expert Opin Investig Drugs. 2011 Nov;20(11):1479-96. doi: 10.1517/13543784.2011.623697. Epub 2011 Sep 28. Expert Opin Investig Drugs. 2011. PMID: 21955127
Q&A: Bernard Munos.
Bender E. Bender E. Nature. 2016 May 12;533(7602):S59. doi: 10.1038/533S59a. Nature. 2016. PMID: 27167392 No abstract available.
Biomedicine. Pharma firms push for sharing of cancer trial data.
Bhattacharjee Y. Bhattacharjee Y. Science. 2012 Oct 5;338(6103):29. doi: 10.1126/science.338.6103.29. Science. 2012. PMID: 23042862 No abstract available.
[Open innovation and licensing in the pharmaceutical industry].
Yamasaki M. Yamasaki M. Nihon Yakurigaku Zasshi. 2013 Jul;142(1):28-31. doi: 10.1254/fpj.142.28. Nihon Yakurigaku Zasshi. 2013. PMID: 23842225 Review. Japanese. No abstract available.
Can open-source drug R&D repower pharmaceutical innovation?
Munos B. Munos B. Clin Pharmacol Ther. 2010 May;87(5):534-6. doi: 10.1038/clpt.2010.26. Clin Pharmacol Ther. 2010. PMID: 20407458 Review.

See all similar articles

Cited by

Target mRNA inhibition by oligonucleotide drugs in man.
Lightfoot HL, Hall J. Lightfoot HL, et al. Nucleic Acids Res. 2012 Nov;40(21):10585-95. doi: 10.1093/nar/gks861. Epub 2012 Sep 18. Nucleic Acids Res. 2012. PMID: 22989709 Free PMC article.
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target.
Islam S, Wang S, Bowden N, Martin J, Head R. Islam S, et al. Br J Clin Pharmacol. 2022 Jan;88(1):64-74. doi: 10.1111/bcp.14964. Epub 2021 Jul 9. Br J Clin Pharmacol. 2022. PMID: 34192364 Free PMC article. Review.
"Digital biomarkers" in preclinical heart failure models - a further step towards improved translational research.
Schmidt A, Balitzki J, Grmaca L, Vogel J, Boehme P, Boden K, Hüser J, Truebel H, Mondritzki T. Schmidt A, et al. Heart Fail Rev. 2023 Jan;28(1):249-260. doi: 10.1007/s10741-022-10264-4. Epub 2022 Aug 24. Heart Fail Rev. 2023. PMID: 36001250 Free PMC article. Review.
Report from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013.
Testori A, Ascierto P, Chiarion Sileni V, De Lorenzo F, Pelicci P, Rossi C. Testori A, et al. Ecancermedicalscience. 2014 Jun 30;8:440. doi: 10.3332/ecancer.2014.440. eCollection 2014. Ecancermedicalscience. 2014. PMID: 25075214 Free PMC article.
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population.
Pauwels K, Huys I, Casteels M, Denier Y, Vandebroek M, Simoens S. Pauwels K, et al. Appl Health Econ Health Policy. 2019 Dec;17(6):895-902. doi: 10.1007/s40258-019-00504-4. Appl Health Econ Health Policy. 2019. PMID: 31359269 Free PMC article.

See all "Cited by" articles

References

1. Nat Rev Drug Discov. 2009 Aug;8(8):609-10 - PubMed
1. Nat Rev Drug Discov. 2010 Mar;9(3):203-14 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group